AbbVie
ABBV
$222.47
+0.40%
AbbVie is a global pharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and aesthetics, following its spin-off from Abbott in 2013. The company is a market leader in immunology with blockbuster drugs Skyrizi and Rinvoq, and has fortified its pipeline through strategic acquisitions like Cerevel and ImmunoGen. The current investor narrative is focused on the successful transition away from Humira's patent cliff, with robust growth from its immunology franchise offsetting biosimilar erosion, while recent news highlights pipeline advancements in obesity and Crohn's disease alongside regulatory challenges for new aesthetics products.…
ABBV
AbbVie
$222.47
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating & Thesis: AbbVie is a Buy for value-oriented investors seeking a defensive large-cap pharma with a clear path to earnings recovery and a solid dividend, as supported by the bullish analyst consensus and recent upgrades. The core thesis is that the market is mispricing the stock based on distorted trailing earnings, while the forward P/E of 14.01x offers an attractive entry point for normalized profit growth led by Skyrizi and Rinvoq.
Supporting Evidence: This Buy recommendation is grounded in four specific data points. First, the forward P/E of 14.01x is reasonable relative to peers and implies significant earnings expansion from the trailing P/E of 96.26x. Second, revenue growth is robust at 10.04% YoY in Q4 2025, demonstrating successful navigation of the Humira patent cliff. Third, profitability is poised for a sharp rebound, with Q4 2025 gross margin expanding to 84.02% from 66.38% in Q3. Fourth, the company's financial foundation is strong, evidenced by $18.70B in TTM free cash flow, which supports the 2.87% dividend yield and strategic M&A.
Risks & Conditions: The two biggest risks to this thesis are persistent earnings volatility from further one-time charges and accelerated competitive erosion in immunology. This Buy rating would downgrade to Hold if forward EPS fails to converge toward the $20.11 estimate, or if quarterly revenue growth decelerates below 5%. It would downgrade to Sell if the immunology franchise shows signs of stalling or if liquidity tightens further (current ratio falling below 0.5). Relative to its history and the forward earnings power implied by its growth assets, the stock is fairly valued to slightly undervalued.
Sign up to view all
ABBV 12-Month Price Forecast
The AI assessment is bullish with medium confidence, based on a compelling risk/reward setup. The stock is priced for normalized earnings that appear achievable given the underlying strength of Skyrizi and Rinvoq. The low beta and strong cash flow provide downside protection, while the forward P/E offers attractive upside if execution continues. Confidence is tempered by the recent history of earnings volatility and the ever-present threat of pharmaceutical competition. The stance would upgrade to bullish with high confidence on a sustained breakout above $245 (the 52-week high) on strong volume, confirming the technical reversal. It would downgrade to neutral if the stock fails to hold above $210 or if next quarter's revenue growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $289.21 and implied upside of +30.0% versus the current price.
Average Target
$289.21
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$178 - $289
Analyst target range
Analyst coverage is moderate with 12 firms providing estimates, indicating sustained institutional interest. The consensus sentiment is bullish, as evidenced by recent ratings from major firms like Morgan Stanley ('Overweight') and Piper Sandler ('Overweight'), though some maintain a 'Neutral' stance. The average revenue estimate for the next period is $83.73 billion, with a tight range between $82.02 billion and $84.89 billion, signaling strong conviction in the top-line outlook. The full target price range is not explicitly provided in the data, but the narrow band of revenue estimates suggests analysts have a high degree of agreement on the company's fundamental trajectory, reducing uncertainty; the recent upgrade from HSBC from 'Hold' to 'Buy' in December 2025 further underscores a positive shift in sentiment.
Bulls vs Bears: ABBV Investment Factors
The bull and bear cases for AbbVie are sharply defined by the tension between its forward-looking fundamentals and its distorted recent financials. The bull side has stronger evidence, anchored in the compelling forward P/E of 14x, robust immunology growth replacing Humira, and massive free cash flow generation. However, the bear case is substantiated by extreme earnings volatility, weak liquidity, and rising competitive threats. The single most important factor in the investment debate is the resolution of earnings normalization. If the company can deliver on the forward EPS estimate of $20.11, justifying its low forward multiple, the stock could re-rate significantly higher. Conversely, if one-time charges persist or growth decelerates, the current valuation could prove optimistic.
Bullish
- Strong Forward P/E Valuation: The forward P/E of 14.01x is in line with large-cap pharma peers and represents a significant discount to the distorted trailing P/E of 96.26x. This gap implies the market expects a substantial earnings recovery as one-time charges subside, offering a clear valuation re-rating opportunity.
- Robust Immunology Growth Offsets Humira: Q4 2025 revenue grew 10.04% YoY to $16.62B, driven by Skyrizi ($5.01B) and Rinvoq ($2.37B). This demonstrates successful execution in replacing Humira ($1.25B) and provides a durable growth engine, with recent positive Crohn's data for Skyrizi further strengthening its competitive moat.
- The company generates massive free cash flow of $18.70B TTM, supporting its business, dividend (2.87% yield), and strategic acquisitions. This financial strength provides a margin of safety and funds continued R&D investment in high-potential areas like obesity.
- Low Market Volatility (Beta 0.31): A beta of 0.309 indicates the stock is approximately 69% less volatile than the broader market. This defensive characteristic makes it a relative safe haven during market swings, appealing to risk-averse investors, as evidenced by its recent outperformance (1-month +9.22%) while the SPY declined.
Bearish
- Extreme Earnings Volatility & Distortion: Trailing profitability metrics are severely distorted, with a net margin of 6.91% and a negative ROE of -129.24%. This reflects significant one-time charges and acquisition costs, creating uncertainty around normalized earnings and making historical comparisons misleading.
- Weak Short-Term Liquidity Position: The current ratio of 0.67 indicates tight short-term liquidity, which could constrain operational flexibility. While strong FCF mitigates this, it remains a point of financial vulnerability, especially if the company faces unexpected cash needs.
- Intensifying Competitive Threats: Recent news highlights new competition, such as the FDA approval of Johnson & Johnson's oral psoriasis drug Icotyde, which directly challenges AbbVie's blockbuster Skyrizi. This underscores the perpetual risk of pipeline innovation from rivals eroding market share.
- Regulatory & Pipeline Execution Risks: The company recently faced an FDA rejection for its wrinkle drug TrenibotE due to manufacturing issues. Such setbacks create near-term delays, increase costs, and highlight the non-scientific risks inherent in bringing new products to market.
ABBV Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of +18.35% but a current price of $227.73 sitting only 37.7% above its 52-week low of $181.73, indicating it is trading in the lower half of its annual range. This positioning suggests the stock is recovering from a significant drawdown but remains well off its highs, reflecting ongoing investor caution. Recent momentum shows a sharp recovery, with a strong 1-month gain of +9.22% and a 3-month gain of +3.66%, which diverges positively from the weaker 6-month performance of +1.97%. This recent acceleration suggests a potential trend reversal or a relief rally from oversold conditions, as the price has rebounded from lows near $198 in late April. Key technical levels are clear, with immediate resistance at the 52-week high of $244.81 and support at the 52-week low of $181.73. A breakout above $245 would signal a resumption of the longer-term uptrend, while a breakdown below $182 would indicate a failure of the recent recovery. The stock's beta of 0.309 indicates it is approximately 69% less volatile than the broader market (SPY), which is unusually low for a large-cap pharma and suggests it has acted as a relative safe haven during recent market swings.
Beta
0.31
0.31x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$182-$245
Price range past year
Annual Return
+16.6%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +5.7% | +1.5% |
| 3m | +6.8% | +13.4% |
| 6m | -0.2% | +10.9% |
| 1y | +16.6% | +24.5% |
| ytd | -3.0% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue growth is robust but shows some quarterly volatility; Q4 2025 revenue was $16.62 billion, representing a 10.04% year-over-year increase, though this follows a weaker Q3 where revenue grew only modestly to $15.78 billion. The immunology segment, led by Skyrizi ($5.01 billion) and Rinvoq ($2.37 billion), is the primary growth driver, successfully replacing Humira ($1.25 billion), while aesthetics and neuroscience contribute diversified streams. Profitability is strong but impacted by one-time charges, as evidenced by Q4 net income of $1.82 billion and a gross margin of 84.02%, which expanded significantly from 66.38% in Q3; however, the trailing twelve-month net margin is a more modest 6.91%, reflecting periods of elevated R&D and acquisition-related costs. The balance sheet and cash flow position is solid, with strong free cash flow generation of $18.70 billion TTM supporting the business; however, the debt-to-equity ratio is an extreme -21.12 and return on equity is -129.24%, which are distorted by accounting treatment for large intangible write-downs and retained earnings deficits, while the current ratio of 0.67 indicates manageable but tight short-term liquidity.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 96.26x, while the forward P/E is a much lower 14.01x; this massive gap implies the market expects a significant normalization and recovery in earnings over the next year, likely as one-time charges subside. Compared to industry averages, AbbVie's forward P/E of 14.01x is in line with or at a slight discount to large-cap pharmaceutical peers, which often trade in the low-to-mid teens, suggesting the stock is not priced for premium growth despite its leading immunology franchise. Historically, the current trailing P/E of 96.26x is near the top of its own range over the past several years, which have seen ratios fluctuate wildly due to earnings volatility; this elevated level suggests the market is currently valuing the stock based on depressed trailing earnings rather than forward earnings power, creating a potential value opportunity if normalized profits materialize as expected.
PE
96.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -3572x~551x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's financials present significant near-term risks stemming from extreme earnings volatility and balance sheet distortion. The trailing net margin of 6.91% and a negative Return on Equity of -129.24% reflect the heavy impact of acquisition-related intangible write-downs and other one-off costs, creating uncertainty around sustainable profitability. While free cash flow remains strong at $18.7B TTM, the current ratio of 0.67 indicates a tight liquidity position that could limit operational agility. Furthermore, revenue, though growing, shows quarterly volatility (e.g., Q3 2025 revenue of $15.78B vs. Q4's $16.62B), indicating potential lumpiness in the post-Humira transition.
Market & Competitive Risks: Externally, AbbVie faces intensifying competition and regulatory hurdles. The recent FDA approval of Johnson & Johnson's oral psoriasis drug introduces a new, convenient competitor to Skyrizi, threatening its growth trajectory in a key market. The stock's low beta of 0.309 suggests it is not priced for high growth, leaving it vulnerable to sector rotation out of defensive names if market sentiment turns aggressively bullish. Additionally, regulatory risks are material, as evidenced by the FDA rejection of TrenibotE for manufacturing issues, which can delay pipeline monetization and increase costs.
Worst-Case Scenario: The most damaging scenario would involve a combination of pipeline setbacks, accelerated competitive pressure, and a failure to achieve earnings normalization. Specifically, a major clinical failure in its obesity or neuroscience pipeline, coupled with faster-than-expected market share loss for Skyrizi/Rinvoq, could lead to significant earnings misses and multiple compression. In this adverse scenario, the stock could realistically retreat to its 52-week low of $181.73, representing a downside of approximately -20% from the current price of $227.73. A breach of this level could trigger further technical selling, potentially pushing the stock toward the lows seen during the March 2026 sell-off near $198.
FAQ
The key risks are, in order of severity: 1) Financial Distortion Risk: The severely negative ROE (-129.24%) and volatile margins create uncertainty around true underlying profitability. 2) Competitive Risk: New entrants like J&J's oral psoriasis drug threaten the growth of core assets Skyrizi and Rinvoq. 3) Pipeline/Regulatory Risk: Recent FDA rejections (e.g., TrenibotE) highlight the non-clinical hurdles in bringing products to market. 4) Liquidity Risk: A current ratio of 0.67 indicates tight short-term liquidity, though it is mitigated by strong cash flow.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $235 and $250, as it delivers on analyst EPS estimates of $20.11 and trades at its current forward multiple. The Bull Case (30% probability) targets $255-$275, driven by better-than-expected growth and multiple expansion. The Bear Case (15% probability) risks a drop to $182-$210 if competition intensifies or earnings disappoint. The base case is most likely, predicated on the assumption that the company's immunology franchise continues its steady growth trajectory offsetting Humira's decline.
Based on forward earnings, ABBV appears fairly valued to slightly undervalued. The trailing P/E of 96.26x is misleading due to one-time charges. The relevant metric is the forward P/E of 14.01x, which is in line with or at a slight discount to large-cap pharmaceutical peers. This suggests the market is not assigning a premium for its leading immunology growth, creating potential value. Compared to its own history, the current forward multiple is reasonable given the company is in a post-Humira transition phase. The valuation implies the market expects successful earnings normalization but remains skeptical about sustainable high growth.
ABBV is a good buy for investors seeking a defensive, large-cap pharmaceutical stock with a clear path to earnings recovery and a solid dividend yield of 2.87%. The forward P/E of 14.01x is attractive relative to the sector and the company's growth profile, offering a favorable risk/reward. However, it is less suitable for those who cannot stomach the extreme quarterly earnings volatility reflected in metrics like the negative ROE. The biggest downside risk is a failure to achieve the expected EPS normalization, which could keep the stock range-bound. It is a good buy for patient, long-term investors.
ABBV is unequivocally suitable for a long-term investment horizon, with a suggested minimum holding period of 3-5 years. Its low beta (0.309) and dividend policy make it a poor candidate for short-term trading, as it typically exhibits lower volatility. The investment thesis is based on the multi-year earnings normalization story and the long commercial lifecycle of its biologic drugs. Short-term price movements are often driven by noisy quarterly earnings, but the long-term value is derived from the durability of its immunology franchise and pipeline. Therefore, it is ideal for investors building a core healthcare holding for their portfolio.
